Danish pharmaceutical company Novo Nordisk (NYSE:NVO) announced last week that its diabetes-fighting insulin drug Ryzodeg has been approved for sale in Japan by the Japanese Ministry of Health, Labour, and Welfare.

Ryzodeg is a combination of long-acting insulin agent Tresiba and fast-acting insulin agent NovoRapid -- marketed in the U.S. under the name NovoLog. Nordisk still waits upon FDA approval for Tresiba in the United States. An FDA advisory committee gave a positive opinion of the drug back in November, but it also unanimously voted to advise that Novo Nordisk be required to carry out a study on cardiovascular effects of the drug.

Novo, which some industry observers say could market Tresiba as a potent competitor to Sanofi's (NYSE:SNY) blockbuster insulin drug Lantus, has said such a study would cost in excess of $250 million.


Dan Carroll has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.